Literature DB >> 30765472

Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.

Gianluigi Reda1, Ramona Cassin2, Gabriela Dovrtelova3,4, Cristina Matteo3, Juri Giannotta2, Maurizio D'Incalci3, Agostino Cortelezzi2, Massimo Zucchetti3.   

Abstract

Entities:  

Year:  2019        PMID： 30765472      PMCID： PMC6518888          DOI： 10.3324/haematol.2018.213157

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

Review 1.  Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012.

Authors:  Megan Ratterman; Kimberly Kruczek; Suela Sulo; Tait D Shanafelt; Neil E Kay; Chadi Nabhan
Journal:  Leuk Res       Date:  2013-09-06       Impact factor: 3.156

2.  Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.

Authors:  Anne Wanquet; Rudy Birsen; Richard Lemal; Mathilde Hunault; Véronique Leblond; Thérèse Aurran-Schleinitz
Journal:  Blood       Date:  2016-03-18       Impact factor: 22.113

3.  Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review.

Authors:  Alan A Moazzam; Jan Drappatz; Ryan Y Kim; Santosh Kesari
Journal:  J Neurooncol       Date:  2011-07-17       Impact factor: 4.130

4.  Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.

Authors:  Ahmed Hamed Salem; Suresh K Agarwal; Martin Dunbar; Sari L Heitner Enschede; Rod A Humerickhouse; Shekman L Wong
Journal:  J Clin Pharmacol       Date:  2016-11-15       Impact factor: 3.126

5.  Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.

Authors:  Ahmed Hamed Salem; Beibei Hu; Kevin J Freise; Suresh K Agarwal; Dilraj S Sidhu; Shekman L Wong
Journal:  Clin Drug Investig       Date:  2017-03       Impact factor: 2.859

6.  The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Authors:  Mary Ann Anderson; Jing Deng; John F Seymour; Constantine Tam; Su Young Kim; Joshua Fein; Lijian Yu; Jennifer R Brown; David Westerman; Eric G Si; Ian J Majewski; David Segal; Sari L Heitner Enschede; David C S Huang; Matthew S Davids; Anthony Letai; Andrew W Roberts
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

8.  Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story.

Authors:  Arian Emami Riedmaier; David J Lindley; Jeffrey A Hall; Steven Castleberry; Russell T Slade; Patricia Stuart; Robert A Carr; Thomas B Borchardt; Daniel A J Bow; Marjoleen Nijsen
Journal:  J Pharm Sci       Date:  2017-10-06       Impact factor: 3.534

9.  Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia.

Authors:  Paolo Strati; Joon H Uhm; Timothy J Kaufmann; Chadi Nabhan; Sameer A Parikh; Curtis A Hanson; Kari G Chaffee; Timothy G Call; Tait D Shanafelt
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941
  9 in total
  14 in total

1.  Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement.

Authors:  Annalisa Condorelli; Cristina Matteo; Salvatore Leotta; Giovanni Schininà; Roberta Sciortino; Gianna Maria Piccolo; Nunziatina Laura Parrinello; Maria Proietto; Maria Grazia Camuglia; Massimo Zucchetti; Giuseppe Milone; Francesco Di Raimondo
Journal:  Cancer Chemother Pharmacol       Date:  2021-09-29       Impact factor: 3.288

Review 2.  What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?

Authors:  Kerstin Brinkmann; Ashley P Ng; Carolyn A de Graaf; Andreas Strasser
Journal:  Cell Death Differ       Date:  2022-04-06       Impact factor: 12.067

Review 3.  Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:  Lesley J Scott
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

4.  Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement.

Authors:  Nishika Karbhari; Hugo Lara-Martinez; John M Hill
Journal:  Case Rep Oncol       Date:  2022-03-30

5.  Venetoclax with high-dose methotrexate and rituximab seem effective and well-tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report.

Authors:  Guillaume Beziat; Martin Gauthier; Caroline Protin; Lucie Oberic; Fleur Lerebours; Jasmine Carlier; Loïc Ysebaert
Journal:  Clin Case Rep       Date:  2020-01-10

Review 6.  Therapeutic drug monitoring of oral targeted antineoplastic drugs.

Authors:  Anna Mueller-Schoell; Stefanie L Groenland; Oliver Scherf-Clavel; Madelé van Dyk; Wilhelm Huisinga; Robin Michelet; Ulrich Jaehde; Neeltje Steeghs; Alwin D R Huitema; Charlotte Kloft
Journal:  Eur J Clin Pharmacol       Date:  2020-11-09       Impact factor: 2.953

7.  Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood-brain barrier be a disease "sanctuary" during venetoclax treatment?

Authors:  Maria Dimou; Aikaterini Bitsani; Maria Roumelioti; Aglaia Dimitrakopoulou; Theodore Iliakis; Vasileios Pardalis; Ioannis Grafakos; Sotiria Kalyva; Athanasios Markopoulos; Marie-Christine Kyrtsonis; Panayiotis Panayiotidis
Journal:  Clin Case Rep       Date:  2021-03-04

8.  Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report.

Authors:  Xuzhao Zhang; Jinliang Chen; Weiqin Wang; Xian Li; Yanbin Tan; Xiaohong Zhang; Wenbin Qian
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

Review 9.  Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature.

Authors:  Nil Albiol; Silvana Novelli; Anna Mozos; Marta Pratcorona; Rodrigo Martino; Jorge Sierra
Journal:  J Med Case Rep       Date:  2021-06-26

Review 10.  Multiple myeloma with central nervous system relapse.

Authors:  Philip A Egan; Patrick T Elder; W Ian Deighan; Sheila J M O'Connor; H Denis Alexander
Journal:  Haematologica       Date:  2020-05-15       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.